医院多西他赛不良反应发生情况

Adverse Reactions of Docetaxel in Hospitals

目的探讨使用多西他赛出现的药物不良反应(ADR)发生特点和影响因素。方法利用阜新矿总医院医院信息系统(HIS)导出2013年1月至2018年12月该院应用多西他赛进行治疗的患者的病例,收集多西他赛相关ADR并进行回顾性分析。结果在获取的273例病例中,52例患者出现多西他赛相关ADR,其中男16例,女36例;40~55岁患者ADR发生率最高,为28.26%;体表面积与多西他赛的体内过程无直接关联;乳腺癌在全部原患肿瘤中排名第一,ADR上报15例(32.61%);使用剂量>75 mg/m^2患者ADR发生率最高,发生率为33.33%,其中骨髓抑制发生率22.22%;多西他赛联合铂类药物ADR发生例数最多,为26例,占25.00%;多西他赛引发ADR最常见的累及器官为血液系统,共计34例次,占55.74%,最常见的临床表现为骨髓抑制。结论不同个体采用多西他赛进行治疗出现的ADR差异较大,并且影响因素较多,临床应根据患者个体情况进行早期评估和用药监控,从而降低患者ADR发生率,提高患者满意度。

Objective To explore the occrurance characteristics and influential factors of adverse drug reactions(ADR)of docetaxel.Methods Records of patients with docetaxel were extracted by using HIS system in General Hospital under Fuxin Mining Bureau from Jan.2013 to Dec.2018.ADR related to docetaxel were collected and analyzed retrospectively.Results Among 273 cases obtained,ADRs related to docetaxel occurred in 52 patients(16 males and 36 females).Patients aged 40-55 years have the highest incidence of ADR(28.26%).Body surface area is not directly related to the intracorporal process of docetaxel.Breast cancer ranked first among all the primary tumors,with 15 reported ADR cases(32.61%).The incidence of ADR was highest in patients with a dosage of>75 mg/m^2,with an incidence of 33.33%,of which the incidence of bone marrow suppression was 22.22%.Docetaxel combined with platinum drugs has the largest number of ADR cases,accounting for 25%.The most common organ involved in ADR caused by docetaxel is the blood system,with a total of 34 cases,accounting for 55.74%.The most common clinical manifestation is bone marrow suppression.Conclusion The individual differences of docetaxel related ADR are great and affected by many factors.Individual physical condition of patients should be taken into consideration as early as possible,which can reduce the incidence of ADR and improve the patients’satisfaction.